Amwill Health Care Ltd

As of November 7, 2025, Amwill Health is considered undervalued with a PE ratio of 9.06 and strong return metrics, making it very attractive compared to peers like Sun Pharma and Dr. Reddy's Labs.

Amwill Health's historical performance shows fluctuating financial metrics, with net sales rising to 43.95 Cr in Mar'24 before declining to 40.58 Cr in Mar'25. Despite growth in total assets and improved cash flow, profitability metrics such as operating profit and profit after tax decreased in the latest fiscal year.

Amwill Health will announce its results on November 4, 2025.

Amwill Health's historical performance shows growth in net sales and operating profit from Mar'22 to Mar'24, but a decline in these metrics in Mar'25. Total assets and liabilities increased significantly, while cash flow fluctuated, indicating challenges in maintaining profitability recently.

As of October 24, 2025, Amwill Health is fairly valued with a PE ratio of 9.69, significantly lower than peers like Sun Pharma and Dr. Reddy's Labs, but has underperformed recently with an 11.79% decline over the past month.

As of October 24, 2025, Amwill Health is fairly valued with a PE ratio of 9.69, lower than competitors like Sun Pharma and Dr. Reddy's Labs, but has underperformed the Sensex over the past month.

As of October 24, 2025, Amwill Health is fairly valued with a PE ratio of 9.69 and has recently outperformed the Sensex over the past week, despite a monthly decline of 11.79%.

As of 17-Oct, Amwill Health Care Ltd's stock price is Rs 51.50, down 4.45%, and has underperformed significantly, trading below key moving averages and nearing its 52-week low. Despite increased investor participation, the stock's performance remains weak compared to the broader market, which has shown positive returns.

As of 10-Oct, Amwill Health Care Ltd's stock is priced at Rs 54.50, up 3.67%, but it is below several key moving averages and has seen a significant drop in investor participation. While it has gained 4.33% over the past week, its longer-term performance is lagging behind the market benchmark.

As of 30-Sep, Amwill Health Care Ltd's stock price is Rs. 53.01, down 4.49% and at a 52-week low. The stock has declined 10.08% over the last four days, underperformed its sector, and is trading below all moving averages, indicating a bearish trend despite increased investor participation.

As of 24-Sep, Amwill Health Care Ltd is priced at 58.95, having increased by 1.9%. Despite a recent uptick, the stock has underperformed over the past week and month, with significant drops in investor participation, suggesting concerns about its future performance.

As of 23-Sep, Amwill Health Care Ltd's stock is priced at 58.20, down 1.36%, and has underperformed its sector and the Sensex. The stock shows declining investor participation and erratic trading patterns, indicating negative sentiment and a challenging environment.

As of 22-Sep, Amwill Health Care Ltd's stock price is at 59.00, unchanged, with mixed short-term performance: a 1.92% gain over the past week but a 3.12% decline over the past month. Despite outperforming its sector today, the stock has seen erratic trading and a significant drop in delivery volume, indicating reduced investor interest.

As of September 18, 2025, Amwill Health is fairly valued at a price of 59.00, with a PE ratio of 11.00 and strong financial metrics, making it a competitive investment opportunity despite a recent slight decline in stock performance.

As of 18-Sep, Amwill Health Care Ltd's stock price is Rs 59.00, down 6.19%, indicating underperformance against its sector and a significant drop in investor participation. The stock has reversed its trend after three days of gains and shows a negative monthly return, contrasting with the positive performance of the Sensex.

As of 17-Sep, Amwill Health Care Ltd's stock price is at 62.89, having increased by 1.6% recently. The stock has outperformed the Sensex and its sector over the past week, but remains below its long-term moving averages, indicating potential challenges ahead.

As of September 16, 2025, Amwill Health is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 11.54, an EV to EBITDA of 10.36, and a Price to Book Value of 1.79, despite outperforming the Sensex recently.

As of 16-Sep, Amwill Health Care Ltd's stock price is Rs 61.90, up 6.93% today and outperforming its sector. Despite a recent short-term rally, the stock has declined by 0.96% over the past month, underperforming the Sensex.

As of 15-Sep, Amwill Health Care Ltd's stock price is Rs. 57.89, having recovered from an intraday low of Rs. 53.85. Despite today's gain, the stock has declined 7.38% over the past month, indicating ongoing challenges in performance relative to the market.